Berry Global has announced a significant expansion of its European healthcare production footprint.
Investments in three key sites will increase production capacity by up to 30%, further solidifying Berry’s commitment to the healthcare sector.
Go deeper with GlobalData
This expansion follows the recent opening of a new manufacturing facility and healthcare centre of excellence in Bangalore, India.
The European investments demonstrate Berry’s dedication to providing high-quality packaging and drug delivery devices that enhance the patient experience through improved medication administration and adherence.
“As pharmaceutical innovations progress, so should the packaging and support that delivers each dose. Berry Global is here to provide that expertise in the creation of patient-centred packages and drug delivery device design,” said Walid Hamza, EVP Global Healthcare at Berry Global.
“We continue to invest in the latest healthcare technologies to help our customers offer patients a safe and improved experience with every dose.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataStrategically located near major pharmaceutical hubs, Berry’s facilities in Offranville, France, and Osnago, Italy, are well-positioned to deliver fast response times and localised service.
The company said the investments will ensure supply chain reliability and consistent product availability to meet the growing global demand for Berry’s healthcare production solutions.
The Offranville site specialises in best-in-class standard and custom pharmaceutical packaging and drug delivery devices, including ophthalmic and nasal products.
Key investments here include the creation of new cleanroom production spaces meeting ISO7 standards. This expansion strengthens Berry’s capabilities as a contract development and manufacturing organisation (CDMO), allowing them to better serve a wider range of clients.
Investments at the Osnago and Sirone facilities, which manufacture throat spray actuators and accompanying bottles respectively, address the rising demand for orally-administered solutions for respiratory illnesses and infections. This trend is partly driven by increasing air pollution levels around the world.
By expanding its European production capacity, Berry Global is well-positioned to meet the evolving needs of the healthcare industry and deliver innovative production solutions that improve patient outcomes.
